Joint venture · MENA · Announced 5 Nov 2026
Dawah Pharma → HoldiPharma
Egypt's Cabinet approved state-owned HoldiPharma setting up Dawa Holdy, a joint-stock company with US-based Dawah Pharma, to make and export food supplements, medical consumables and selected medicines from HoldiPharma plants.
Parties: Dawah Pharma (United States) → HoldiPharma (Egypt)
- Deal type
- Joint venture
- Value
- Undisclosed
- Territory
- Egypt production base; sales in Egypt and exports to Africa, Europe, Canada and the United States
- Therapeutic area
- Multi-therapy
- Assets
- Food supplements; Medical consumables; Selected medicines
- Announced
- 5 Nov 2026
Our analysis
Why this matters
On 5 November 2026, Egypt's Cabinet approved a recommendation from the State-Owned Companies Unit allowing the Holding Company for Pharmaceuticals, Chemicals and Medical Supplies (HoldiPharma) to establish a new joint-stock company, "Dawa Holdy for Pharmaceutical Trade and Distribution", with US-based Dawah Pharma. The company will manage and develop pharmaceutical manufacturing projects, make food supplements and medicines under contract at HoldiPharma subsidiaries, market and export supplements and medical consumables, and upgrade some of the group's factories and production lines. Sales are planned in Egypt and for export to Africa, Europe, Canada and the United States, in three stages.
The approval formalises a shareholders' agreement signed in May 2025 in the presence of Prime Minister Mostafa Madbouly. Reports at the time put the split at 60% Dawah Pharma and 40% HoldiPharma, with an initial six food-supplement products for the US market and later phases covering ampoules, sterile injectables, eye preparations and OTC medicines to FDA and EMA standards.
The full analysis is free to read with a work email on this page.